Safety of Subcutaneous Administration of Rituximab during the First-Line Treatment of Patients with Non-Hodgkin Lymphoma: The MabRella Study

被引：2
|
作者：
Panizo, Carlos [1 ]
Bekadja, Mohamed Amine [2 ]
Meddeb, Balkis [3 ]
Mendoza, Maria Rigoroso [4 ]
Truman, Matt [5 ]
Smith, Rodney [4 ]
Barate, Claudia [6 ]
机构：
[1] Clin Univ Navarra, Pamplona, Spain
[2] Univ Hosp Estab, Oran, Algeria
[3] Aziza Othmana Univ Hosp, Tunis, Tunisia
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] F Hoffmann La Roche Ltd, Dee Why, Australia
[6] Univ Pisa, Pisa, Italy
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2971.2971
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2971
引用
收藏
页数：5
相关论文
共 50 条
  • [1] SAFETY OF SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB DURING THE FIRST-LINE TREATMENT OF PATIENTS WITH NON-HODGKIN LYMPHOMA: THE MABRELLA STUDY
    Panizo, C.
    Bekadja, M. A.
    Meddeb, B.
    Meier, O.
    Smith, R.
    Truman, M.
    Barate, C.
    HAEMATOLOGICA, 2017, 102 : 252 - 253
  • [2] Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
    Garcia-Munoz, Ricardo
    Quero, Cristina
    Perez-Persona, Ernesto
    Domingo-Garcia, Abel
    Perez-Lopez, Cristina
    Villaescusa-de-la-Rosa, Teresa
    Martinez-Castro, Ana M.
    Arguinano-Perez, Jose M.
    Parra-Cuadrado, Juan F.
    Panizo, Carlos
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (05) : 661 - 673
  • [3] First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma
    Hainsworth, JD
    SEMINARS IN ONCOLOGY, 2003, 30 (01) : 9 - 15
  • [4] EFFICACY AND SAFETY OF BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH INDOLENT NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA
    Cencini, E.
    Fabbri, A.
    Iannuzzi, A.
    Schiattone, L.
    Brambilla, C. Zuanelli
    Bocchia, M.
    HAEMATOLOGICA, 2017, 102 : 112 - 112
  • [5] Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma
    Hainsworth, JD
    Litchy, S
    Burris, HA
    Scullin, DC
    Corso, SW
    Yardley, DA
    Morrissey, L
    Greco, FA
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) : 4261 - 4267
  • [6] A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma
    MacDonald, D.
    Crosbie, T.
    Christofides, A.
    Assaily, W.
    Wiernikowski, J.
    CURRENT ONCOLOGY, 2017, 24 (01) : 33 - 39
  • [7] Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
    Dundar, Y.
    Bagust, A.
    Hounsome, J.
    McLeod, C.
    Boland, A.
    Davis, H.
    Walley, T.
    Dickson, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 23 - 28
  • [8] Radioimmunotherapy effective first-line treatment for non-Hodgkin's lymphoma
    不详
    ONCOLOGY-NEW YORK, 2000, 14 (07): : 1009 - +
  • [9] Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin's Lymphoma A NICE Single Technology Appraisal
    Greenhalgh, Janette
    Bagust, Adrian
    Boland, Angela
    Blundell, Michaela
    Oyee, James
    Beale, Sophie
    Dundar, Yenal
    Hockenhull, Juliet
    Proudlove, Chris
    Chu, Patrick
    PHARMACOECONOMICS, 2013, 31 (05) : 403 - 413
  • [10] Bendamustine In Combination With Rituximab As First-Line Treatment For Indolent Non-Hodgkin Lymphoma: Retrospective Analysis Of An Spanish Registry
    Solorzano, Silvia
    Martinez-Chamorro, Carmen
    Panizo, Carlos
    Quero, Cristina
    Deben, Guillermo
    Paz, Jose
    Batile, Ana
    Serrano, Alfons
    Muentes, Zayda
    Gutierrez, Antonio
    Tomas, Jose Francisco
    BLOOD, 2013, 122 (21)
12345